MyFinsight
Home
Blog
About
Contact
Download
Download image
Proceeds from stock
option exercises
$516K
Proceeds from common
stock issuances under...
$176K
Other
$19K
Net cash used in
financing activities
$711K
Net decrease in
cash, cash...
-$43,191K
Canceled cashflow
$711K
Stock-based compensation
$5,547K
Accounts payable
$1,289K
Depreciation expense
$295K
Non-cash lease expense
$285K
Non-cash change in fair
value of term loan
$32K
Other
-$27K
Net cash used in
operating activities
-$40,878K
Net cash used in
investing activities
-$3,024K
Canceled cashflow
$7,475K
Net loss
-$42,410K
Purchase of research and
development license
$3,000K
Purchase of property,
plant and equipment
$24K
Accrued expenses and
other liabilities
-$5,149K
Prepaid expenses and
other assets
$794K
Back
Back
Cash Flow
source: myfinsight.com
Taysha Gene Therapies, Inc. (TSHA)
Taysha Gene Therapies, Inc. (TSHA)